Aerosol delivery in interstitial lung diseases - breakthrough or lost cause?

References

• Antoine MH, Mlika M. 2024 Apr 20. Interstitial lung disease [internet. In: StatPearls. StatPearls Publishing; Available from: https://www.ncbi.nlm.nih.gov/books/NBK541084/
   Google Scholar
• Zeng Q, Jiang D. Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the global burden of disease study 2019, and projections until 2030. Front Med. 2023;10:1141372. doi: 10.3389/fmed.2023.1141372
   Google Scholar
• Chen X, Guo J, Yu D, et al. Predictors of mortality in progressive fibrosing interstitial lung diseases. Front Pharmacol. 2021;12:754851. doi: 10.3389/fphar.2021.754851
   PubMed Web of Science ®Google Scholar
• Johannson KA, Chaudhuri N, Adegunsoye A, et al. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet. 2021;398(10309):1450–1460. doi: 10.1016/S0140-6736(21)01826-2
   PubMed Web of Science ®Google Scholar
• Amati F, Stainer A, Polelli V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci. 2023;24(9):7849. doi: 10.3390/ijms24097849
   PubMed Web of Science ®Google Scholar
• Sotiropoulou V, Karampitsakos T, Katsaras M, et al. What is new in the treatment of interstitial lung diseases. Pneumon. 2023;36(2):14. doi: 10.18332/pne/161867
   Web of Science ®Google Scholar
• Guo H, Sun J, Zhang S, et al. Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies. Front Pharmacol. 2023;14:1205948. doi: 10.3389/fphar.2023.1205948
   PubMed Web of Science ®Google Scholar
• Maher TM, Nambiar AM, Wells AU. The role of precision medicine in interstitial lung disease. Eur Respir J. 2022;60(3):2102146. doi: 10.1183/13993003.02146-2021
   PubMed Web of Science ®Google Scholar
• Finlay WH. Deposition of aerosols in the lungs: particle characteristics. J Aerosol Med Pulm Drug Deliv. 2021 Aug;34(4):213–216. doi: 10.1089/jamp.2021.29040.whf
   PubMed Web of Science ®Google Scholar
• Sanchis J, Corrigan C, Levy ML, et al. Inhaler devices - from theory to practice. Respir med. 2013 Apr;107(4):495–502. doi: 10.1016/j.rmed.2012.12.007
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Yang S, et al. The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis. Respir Res. 2018 Feb 6;19(1):25. doi: 10.1186/s12931-018-0732-0
   PubMedGoogle Scholar
• Wright CE, Fraser SD, Brindle K, et al. Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study. ERJ Open Res. 2017 Dec 14;3(4):00100–2017. doi: 10.1183/23120541.00100-2017
   PubMedGoogle Scholar
• Martin AR. Regional deposition: targeting. J Aerosol Med Pulm Drug Deliv. 2021 Feb;34(1):1–10. doi: 10.1089/jamp.2021.29033.am
   PubMed Web of Science ®Google Scholar
• de Kruijf W, Ehrhardt C, Inhalation delivery of complex drugs-the next steps. Curr Opin Pharmacol. 2017 Oct;36:52–57. doi: 10.1016/j.coph.2017.07.015
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi: 10.1016/S0140-6736(11)60405-4
   PubMed Web of Science ®Google Scholar
• Khoo JK, Montgomery AB, Otto KL, et al. A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study of aerosolized pirfenidone delivered via the PARI Investigational eFlow nebulizer in volunteers and patients with idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2020 Feb;33:(1):15–20.
   PubMed Web of Science ®Google Scholar
• Avalyn Pharma News [Internet]. c2010-2024. Avalyn presents data from its AP01 and AP02 inhaled therapeutics programs for pulmonary fibrosis. Seattle (WA): Avalyn Pharma Inc; 2023 Nov 9 [cited 2024 Apr 23]; [About 6 screens]. Available from: https://www.avalynpharma.com/avalyn-presents-data-from-its-ap01-and-ap02-inhaled-therapeutics-programs-for-pulmonary-fibrosis/
   Google Scholar
• Dempsey TM, Thao V, Moriarty JP, et al. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States. BMC Pulm Med. 2022;22(1):18. doi: 10.1186/s12890-021-01811-0
   PubMed Web of Science ®Google Scholar
• Humphries B, Saunders M, Cruwys S. Inhaled NXP002 attenuates LPS-induced inflammatory and fibrotic mediator production in the rat lung. Eur Respir J. 2022;60(Suppl 66):2955. doi: 10.1183/13993003.congress-2022.2955
   Google Scholar
• Avalyn Pipeline [Internet]. c2010-2024. Inhaled nintedanib. Seattle (WA): Avalyn Pharma Inc.; [cited 2024 Apr 24]; [About 1 screen] Available from: https://www.avalynpharma.com/ap03/
   Google Scholar
• Avalyn Pipeline [Internet]. c2010-2024. Inhaled nintedanib dry-powder. Seattle (WA): Avalyn Pharma Inc.; [cited 2024 Apr 24]; [About 1 screen]. Available from: https://www.avalynpharma.com/ap02-dp/
   Google Scholar
• Timaner M, Fishman-Jacob T, Pertzov B, et al. Harnessing the therapeutic power of secretomes to treat IPF. Eur Respir J. 2022;60(Suppl 66):427. doi: 10.1183/13993003.congress-2022.427
   Google Scholar
• UKRI Gateway [Internet]. c2018-2024. development of inhaled, dual EP2/4 receptor agonists for the treatment of idiopathic pulmonary fibrosis. Swindon (UK): UK Research and Innovation; 2021 Sep 1 [cited 2024 Apr 24]; [about 2 screens]. Available from: https://gtr.ukri.org/projects?ref=MR%2FV005928%2F1
   Google Scholar
• Ghanem M, Justet A, Archer G, et al. Inhaled FGF19 therapy in pulmonary fibrosis. 2023 ;207: A4708. doi:10.1164/ajrccm-conference.2023.207.135
   Google Scholar
• Pulmonary fibrosis news [internet]. c2013-2024. Novel NOX4 blockers could treat fibrosis at the source, scientists Say. Pensacola (FL): BioNews Inc. 2018 Mar 4 [cited 2024 Apr 24]; [about 2 pages] Available from: https://pulmonaryfibrosisnews.com/news/novel-nox4-blockers-could-treat-fibrosis-at-the-source-scientists-say/
   Google Scholar
• Globenewswire [Internet]. c1998-2024. VYNE Therapeutics Announces Positive Preclinical Data for inhaled formulation of VYN201 in an in vivo Model of idiopathic pulmonary fibrosis. Los Angeles (CA): Globenewswire; 2023 Apr 19 [cited 2024 Apr 24]; [about 14 pages].Available from: https://www.globenewswire.com/news-release/2023/04/19/2649968/0/en/VYNE-Therapeutics-Announces-Positive-Preclinical-Data-for-Inhaled-Formulation-of-VYN201-in-an-In-Vivo-Model-of-Idiopathic-Pulmonary-Fibrosis.html
   Google Scholar
• Diwan R, Bhatt HN, Beaven E, et al. Emerging delivery approaches for targeted pulmonary fibrosis treatment. Adv Drug Deliv Rev. 2024 Jan;204:115147. doi: 10.1016/j.addr.2023.115147
   PubMed Web of Science ®Google Scholar
• West A, Chaudhuri N, Barczyk A, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882–889. doi: 10.1136/thorax-2022-219391
   PubMedGoogle Scholar
• Pirfenidone inhalation - Avalyn Pharmaceuticals [internet]. Auckland: Adis International Ltd.; 2023 [cited 18 Nov 2023] Available from: https://adisinsight.springer.com/drugs/800051428
   Google Scholar
• Olitigaltin - Galecto Inc [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800041385
   Google Scholar
• GSK 3008348 [Internet]. Auckland: Adis International Ltd.; 2023 [2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800043800
   Google Scholar
• Epstein-Shochet G, Pham S, Beck S, et al. Inhalation: a means to explore and optimize nintedanib’s pharmacokinetic/pharmacodynamic relationship. Pulm Pharmacol Ther. 2020 Aug;63:101933. doi: 10.1016/j.pupt.2020.101933
   PubMed Web of Science ®Google Scholar
• Nintedanib inhalation - Avalyn Pharmaceuticals [internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800058406
   Google Scholar
• ARO MMP7 [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800068689
   Google Scholar
• PRS 220 [Internet]. Auckland: Adis International Ltd.; 2023 [cited 2023 Nov 18] Available from: https://adisinsight.springer.com/drugs/800064388
   Google Scholar
• Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022 Jul;9(1):e001310. doi: 10.1136/bmjresp-2022-001310
   PubMed Web of Science ®Google Scholar